Circassia Pharmaceuticals (NIOX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst James Orsborne from Stifel Nicolaus maintained a Buy rating on the stock and has a p77.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
James Orsborne has given his Buy rating due to a combination of factors, primarily centered around the recent developments involving Circassia Pharmaceuticals. The company has received a potential all-cash offer from Keensight Capital, valuing the business at £322 million, which translates to approximately 20 times the 2025 consensus EV/EBITDA. This valuation is slightly above the two-year average, indicating a favorable opportunity for shareholders.
Additionally, the possibility of competing bids from other interested parties suggests that the company’s market value could increase further. The offer price of 81p per share, although modestly above the previous tender offer, still represents a good value for a single-product company in this sector. These factors collectively contribute to Orsborne’s positive outlook and Buy rating for Circassia Pharmaceuticals.
According to TipRanks, Orsborne is an analyst with an average return of -22.3% and a 20.00% success rate.